A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents
Jan Philipp Bewersdorf(Memorial Sloan Kettering Cancer Center), Amer M. Zeidan(Yale Cancer Center), Jessica K. Altman(Northwestern University), Joshua F. Zeidner(University of North Carolina at Chapel Hill), Richard Piekarz(Yeshiva University), Jonathan M. Irish(Vanderbilt University), Richard F. Little(Dana-Farber Cancer Institute), Stephanie Halene(Yale Cancer Center), Tae Kon Kim(Vanderbilt University), Olatoyosi Odenike(University of Chicago), Rahul Ramaswamy(Vanderbilt University Medical Center), Caroline E. Roe(Vanderbilt University), Silvia Park(The Catholic University of Korea Seoul St. Mary's Hospital), Swaroopa Yerrabothala(Dartmouth–Hitchcock Medical Center), Abdulraheem Yacoub(The University of Kansas Cancer Center), Wei Wei(New Haven Public Schools), Anne Caldwell(Yale New Haven Hospital), Yazan F. Madanat(The University of Texas Southwestern Medical Center), Rory M. Shallis(Smilow Cancer Hospital), Steven D. Gore(Yale Cancer Center), Nikolai A. Podoltsev, Tibor Kovacsovics(Hôpital Edouard Herriot), Elad Sharon(National Cancer Institute)
Cited by 23
Related Papers
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k